Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs.
Genetic modification of human lymphocytes is being employed in strategies to correct enzyme deficiencies, encode cytokines and to redirect lymphocytes to antigenic targets other than those encoded by their endogenous T cell receptor. However, expression of transgenes in primary lymphocytes is generally low. Reasoning that vector modification may lead to increased transgene expression and subsequent increases in function, we have performed two retroviral vector modifications and report their effect on the functional expression in primary lymphocytes. A chimeric receptor specific for the colon carcinoma-associated antigen, EGP40, was initially incorporated into the retroviral vector LXSN. In this vector, receptor expression is driven by the Moloney murine leukemia virus LTR, and neomycin phosphotransferase expression driven by the SV40 promoter. Replacement of SV40 with an internal ribosomal entry site (IRES) increased the transgene activity of a mouse T cell line and human PBL as judged by increased cytokine release in response to antigen positive target cells. A further increase in transgene function was generated by the additional incorporation of a splice acceptor motif into the construct. Human PBL transduced with vector incorporating both IRES and intron were consistently more effective at lysing antigen positive colorectal carcinoma cells.
Tumor Immunology Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
R E
RE
Royal
M H
MH
Kershaw
M E
ME
Reeves
G
G
Wang
T
T
Daly
J
J
Treisman
J
J
Lam
P
P
Hwu
D000328:Adult; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000235:genetics* / Q000378:metabolism; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology*; D003602:Cytotoxicity, Immunologic; D000071858:Epithelial Cell Adhesion Molecule; D005786:Gene Expression Regulation; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D008979:Moloney murine leukemia virus / Q000235:genetics; D022821:RNA Splice Sites; D014161:Transduction, Genetic; D019076:Transgenes / Q000235:genetics; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; D000071858:Epithelial Cell Adhesion Molecule; D022821:RNA Splice Sites; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor